natgillin/translations-raw huggingface dataset:
Thiotepa undergoes oxidative desulphuration via the cytochrome P450 CYP2B and CYP3A isoenzyme families to the major and active metabolite TEPA (triethylenephosphoramide). 
Tiotepa se oksidativno desulfurira prek izoencimov CYP3A4 in CYP3A citokroma P450 v poglavitni in aktivni metabolit TEPA (trietilenfosforamid).
Therefore, the use of gloves is recommended in preparing the solution for infusion. 
Zato je pri pripravi raztopine za infundiranje priporočljiva uporaba rokavic.
Disease Free Survival (DFS): Percentages of 40% - 75% with follow-up of more than 1 year have been reported. 
Preživetje brez ponovitve bolezni : poročali so o odstotkih med 40 in 75 % za obdobje več kot enega leta.
Cardiovascular insufficiency Cardiac failure 
Srčne bolezni zastoj srca kardiovaskularna insuficienca odpoved srca
Since thiotepa is mainly metabolized through the liver, caution needs to be exercised when thiotepa is used in patients with preexisting impairment of liver function, especially in those with severe hepatic impairment. 
Ker se tiotepa presnavlja predvsem v jetrih, je potrebna previdnost, ko se tiotepa uporablja pri bolnikih s predhodno obstoječo okvaro jetrne funkcije, zlasti pri bolnikih s hudo okvaro jeter.
Contraindications of concomitant use Yellow fever vaccine: risk of fatal generalized vaccine-induced disease. 
Kontraindicirana sočasna uporaba Cepivo proti rumeni mrzlici: tveganje generalizirane, s cepivom sprožene bolezni s smrtnim izidom.
Overall Survival (OS): OS ranged from 50% to 100% with a follow-up ranging from 9.4 up to 121 months. 
Celokupno preživetje: celokupno preživetje je bilo med 50 % in 100 % v obdobju med 9,4 in 121 meseci.
Thiotepa is unreliably absorbed from the gastrointestinal tract: acid instability prevents thiotepa from being administered orally. 
Tiotepa se iz prebavil slabo absorbira: zaradi nestabilnosti v kislem mediju se tiotepe ne uporablja peroralno.
TEPADINA contains the active substance thiotepa, which belongs to a group of medicines called alkylating agents. 
Zdravilo TEPADINA vsebuje učinkovino tiotepa, ki spada v skupino zdravil, imenovanih alkilirajoče učinkovine.
The adverse reactions considered at least possibly related to conditioning treatment including thiotepa, reported in paediatric patients as more than an isolated case, are listed below by system organ class and by frequency. 
Neželeni učinki, ki so vsaj potencialno povezani s pripravljalnim zdravljenjem, ki vključuje tiotepo, in o katerih so poročali pri pediatričnih bolnikih o več kot le o posameznem primeru, so navedeni spodaj glede na organski sistem in pogostnost.
TEPADINA is administered at different doses in combination with other chemotherapeutic medicinal products in patients prior to conventional haematopoietic progenitor cell transplantation (HPCT) for haematological diseases or solid tumours. 
Zdravilo TEPADINA se uporablja v različnih odmerkih, v kombinaciji z drugimi kemoterapevtiki, pri bolnikih pred konvencionalno presaditvijo krvotvornih matičnih celic (PKMC) za hematološke bolezni ali čvrste tumorje.
Caution must be used in patients with history of cardiac diseases, and cardiac function must be monitored regularly in patients receiving thiotepa. 
Previdnost je potrebna pri bolnikih z anamnezo srčnih bolezni, pri bolnikih, ki prejemajo tiotepo, pa je treba redno spremljati delovanje srca.
Leukoencephalopathy 
Levkoencefalopatija
Engraftment: It has been achieved with all reported conditioning regimens including thiotepa. 
Sprejem presadka: dosežen je bil pri vseh režimih pripravljalnega zdravljenja s tiotepo, o katerih so poročali.
- The active substance is thiotepa. 
- Učinkovina je tiotepa.
Thiotepa was shown to impair fertility and interfere with spermatogenesis in male mice, and to impair ovarian function in female mice. 
Tiotepa vpliva na plodnost in sicer pri mišjih samcih na spermatogenezo ter pri mišjih samicah na funkcije jajčnikov.
Calculation of dose of TEPADINA 
Izračun odmerka zdravila TEPADINA
The most serious side effects of TEPADINA therapy or the transplant procedure may include - decrease in circulating blood cell counts (intended effect of the medicine to prepare you for your transplant infusion) - infection - liver disorders including blocking of a liver vein - the graft attacks your body (graft versus host disease) - respiratory complications 
Najbolj resni neželeni učinki zdravljenja z zdravilom TEPADINA ali postopka presaditve lahko vključujejo: - zmanjšanje števila krvnih celic v obtoku (pričakovan učinek zdravila, ki vas pripravi na transplantacijsko infuzijo) - okužbo
The increased risk of a secondary malignancy with thiotepa, a known carcinogen in humans, must be explained to the patient. 
Bolnika je treba obvestiti, da s tiotepo, znano karcinogeno snovjo pri ljudeh, obstaja povečano tveganje sekundarnega malignega obolenja.
TEPADINA must be delivered after the completion of any cyclophosphamide infusion. 
Zdravilo TEPADINA je treba odmeriti po zaključku infundiranja ciklofosfamida.
MULTIPLE MYELOMA 
MULTIPLI MIELOM
If thiotepa solution accidentally contacts the skin, the skin must be immediately and thoroughly washed with soap and water. 
Če raztopina tiotepe nenamerno pride v stik s kožo, kožo nemudoma in temeljito umijte z milom in vodo.
LEUKAEMIA 
LEVKEMIJA
The consequence of treatment with thiotepa at the recommended dose and schedule is profound myelosuppression, occurring in all patients. 
Posledica zdravljenja s tiotepo s priporočenim odmerkom in režimom odmerjanja je močna mielosupresija pri vseh bolnikih.
OVARIAN CANCER 
RAK JAJČNIKOV
Store and transport refrigerated (2°C-8°C). 
Zdravilo shranjujte in prevažajte v hladilniku (2 °C-8 °C).
Thiotepa is a polyfunctional cytotoxic agent related chemically and pharmacologically to the nitrogen mustard. 
Mehanizem delovanja Tiotepa je večfunkcijska citotoksična snov, kemijsko in farmakološko sorodna dušikovemu iperitu.
Type I clear glass vial with a rubber stopper (bromobutyl or chlorobutyl), containing 15 mg thiotepa. 
Viala iz prozornega stekla tipa I z gumijastim zamaškom (bromobutil ali klorobutil), ki vsebuje 15 mg tiotepe.
As most alkylating agents, thiotepa might impair male and female fertility. 
Kot večina alkilirajočih učinkovin lahko tiotepa zmanjša plodnost pri moških in ženskah.
Overall Survival (OS): OS ranged from 17% to 84% with a follow-up ranging from 12.3 up to 99.6 months. 
Celokupno preživetje: celokupno preživetje je bilo med 17 % in 84 % v obdobju med 12,3 in 99,6 meseci.
Uncommon Not known 
Neznana pogostnost
Relapse: In all the reported conditioning regimens containing thiotepa, the relapse rate was in the range of 15% - 44%. 
Ponovitev bolezni: pri vseh režimih pripravljalnega zdravljenja s tiotepo, o katerih so poročali, je bila stopnja ponovitve med 15 in 44 odstotki.
Thiotepa must not be concurrently administered with cyclophosphamide when both medicinal products are present in the same conditioning treatment. 
Tiotepe se ne sme uporabljati hkrati s ciklofosfamidom, če sta obe zdravili prisotni v istem pripravljalnem zdravljenju.
TEPADINA infusion solution should be inspected visually for particulate matter prior to administration. 
Raztopino za infundiranje zdravila TEPADINA je treba pred uporabo vizualno pregledati glede delcev.
How to use TEPADINA 
Kako uporabljati zdravilo TEPADINA
Interaction common to all cytotoxics 
Interakcije, skupne vsem citotoksičnim učinkovinam
Platelet and red blood cell support, as well as the use of growth factors such as Granulocytecolony stimulating factor (G-CSF), should be employed as medically indicated. 
Kadar so prisotne zdravstvene indikacije, je treba nuditi trombocitno in eritrocitno podporo ter uporabiti rastne faktorje, kot je granulocitne kolonije stimulirajoči faktor (G-CSF: Granulocyte-colony stimulating factor).
CSF and plasma concentrations of TEPA, the first reported active metabolite of thiotepa, exceed the concentrations of the parent compound. 
Koncentracije TEPA, prvega aktivnega metabolita tiotepe, o katerem so poročali, v CSF in plazmi , so večje od koncentracij matične spojine.
Frequent complete blood counts, including differential white blood cell counts, and platelet counts need to be performed during the treatment and until recovery is achieved. 
Med zdravljenjem in do okrevanja je treba izvajati pogoste preglede celotne krvne slike, vključno z diferencialno sliko belih krvnih celic in številom trombocitov.
There is no experience with overdoses of thiotepa. 
Izkušenj s prevelikim odmerjanjem tiotepe ni.
Type I clear glass vial with a rubber stopper (bromobutyl or buthyl), containing 100 mg thiotepa. 
Viala iz prozornega stekla tipa I z gumijastim zamaškom (bromobutil ali butil), ki vsebuje 100 mg tiotepe.
Therefore, during the concomitant use of thiotepa and these medicinal products, patients should be carefully monitored clinically. 
Zato je treba bolnike med sočasno uporabo tiotepe in teh zdravil klinično nadzorovati.
Caution must be used in patients with history of renal diseases and periodic monitoring of renal function should be considered during therapy with thiotepa. 
Previdnost je potrebna pri bolnikih z anamnezo ledvičnih bolezni, med zdravljenjem s tiotepo pa je treba redno spremljati delovanje ledvic.
Concomitant use to take into consideration Ciclosporine, tacrolimus: excessive immunosuppression with risk of lymphoproliferation. 
Ciklosporin, takrolimus: čezmerna imunosupresija s tveganjem limfoproliferacije.
Treatment related second malignancy 
z zdravljenjem povezana sekundarna malignost
Topical reactions associated with accidental exposure to thiotepa may occur. 
Lahko se pojavijo lokalne reakcije, povezane z nenamerno izpostavitvijo tiotepi.
Prior to and following each infusion, the indwelling catheter line should be flushed with approximately 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection. 
Pred in po vsakem infudiranju je treba stalni kateter izprati s približno 5 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
Severe toxic skin reactions including cases of StevensJohnson syndrome and toxic epidermal necrolysis 
Hude toksične reakcije kože, vključno s primeri Stevens
Engraftment: Conditioning treatments including thiotepa have proved to be myeloablative. 
Sprejem presadka: pripravljalna zdravljenja s tiotepo so se izkazala za mieloablativna.
Male patients should seek for sperm preservation before therapy is started and should not father a child while treated and during the year after cessation of treatment. 
Moški bolniki naj poskrbijo za shranjevanje sperme pred začetkom terapije, med zdravljenjem in leto dni po prenehanju zdravljenja pa naj ne spočnejo otroka.
After reconstitution the product is stable for 8 hours when stored at 2°C -8°C. 
Po rekonstituciji je zdravilo stabilno 8 ur, če je shranjeno pri temperaturi 2 °C-8 °C.
Cardiomyopathy Myocarditis 
- vnetje srčnega mišičnega tkiva (miokarditis)
Because TEPADINA destroys bone marrow cells responsible for producing blood cells, regular blood tests will be taken during treatment to check your blood cell counts. 
Ker zdravilo TEPADINA uničuje celice kostnega mozga, ki so odgovorne za proizvodnjo krvnih celic,
What TEPADINA looks like and contents of the pack 
Izgled zdravila TEPADINA in vsebina pakiranja
Thiotepa has marrow ablation as its dose-limiting toxicity, allowing significant dose escalation with the infusion of autologous HPCT. 
Toksični učinek tiotepe, odvisen od odmerka, je ablacija mozga, kar omogoča precejšnje stopnjevanje odmerka z infundiranjem avtologne PKMC.
It was teratogenic in mice and in rats, and foeto-lethal in rabbits. 
Je teratogena pri miših in podganah.
In children, if the dose is lower than 250 mg, an appropriate volume of sodium chloride 9 mg/ml (0.9%) solution for injection may be used in order to obtain a final TEPADINA concentration between 0.5 and 1 mg/ml. 
Pri otrocih, pri katerih je odmerek manjši od 250 mg, pripravite ustrezno količino raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje, s katero zagotovite končno koncentracijo zdravila TEPADINA med 0,5 in 1 mg/ml.
Nervous system disorders 
TUMOR OSREDNJEGA ŽIVČNEGA SISTEMA
Male patients should seek for sperm cryopreservation before therapy is started and should not father a child while treated and during the year after cessation of treatment (see section 5.3). 
Moški bolniki naj poskrbijo za shranjevanje sperme z zamrznitvijo pred začetkom zdravljenja, med zdravljenjem in leto dni po prenehanju zdravljenja pa naj ne spočnejo otroka (glejte poglavje 5.3).
You should tell your doctor if you have: - liver or kidney problems, - heart or lung problems, - seizures/fits (epilepsy) or have had them in the past (if treated with phenytoin or fosphenytoin). 
Obvestite svojega zdravnika, če imate: - jetrne ali ledvične težave; - težave s srcem ali pljuči;
It works by destroying bone marrow cells. 
Zdravilo uniči celice kostnega mozga.
As with other cytotoxic compounds, caution need to be exercised in handling and preparation of TEPADINA solutions to avoid accidental contact with skin or mucous membranes. 
Kot pri drugih citotoksičnih spojinah morate biti pri ravnanju z zdravilom TEPADINA in pripravi raztopin zdravila TEPADINA previdni, da se izognete nenamernim stikom s kožo ali sluznico.
Male patients should seek for sperm cryopreservation before therapy is started and should not father a child while treated and during the year after cessation of treatment (see section 4.6). 
Moški bolniki naj poskrbijo za shranjevanje sperme z zamrznitvijo pred začetkom zdravljenja, med zdravljenjem in leto dni po prenehanju zdravljenja pa naj ne spočnejo otroka (glejte poglavje 4.6).
Overall Survival (OS): OS ranged from 29% to 87% with a follow-up ranging from 22 up to 63 months. 
Celokupno preživetje: celokupno preživetje se giblje od 29 % do 87 % za obdobje med 22 in 63 meseci.
After reconstitution, each ml contains 10 mg thiotepa (10 mg/ml). 
Po rekonstituciji en ml vsebuje 10 mg tiotepe (10 mg/ml).
Overall Survival: OS ranged from 30% to 87% with a follow-up ranging from 11.7 up to 87 months. 
Celokupno preživetje: celokupno preživetje je bilo od 30 % do 87 % za obdobje med 11,7 in 87 meseci.
Infection susceptibility increased Sepsis 
- povečana občutljivost za okužbo
Like all medicines, TEPADINA can cause side effects, although not everybody gets them. 
Možni neželeni učinki Kot vsa zdravila ima lahko tudi zdravilo TEPADINA neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being lower than 40% (which was considered by the physicians as the threshold to prove efficacy). 
Ponovitev bolezni: pri vseh pripravljalnih zdravljenjih s tiotepo so poročali o stopnjah ponovitve v obdobju več kot enega leta v višini manj kot 40% (kar zdravniki označujejo kot prag za dokazovanje učinkovitosti).
Overall Survival: OS ranged from 31% to 81% with a follow-up ranging from 7.3 up to 120 months. 
Celokupno preživetje: celokupno preživetje je bilo med 31 % in 81 % za obdobje med 7,3 in 120 meseci.
More generally, live virus and bacterial vaccines must not be administered to a patient receiving an immunosuppressive chemotherapeutic agent and at least three months must elapse between discontinuation of therapy and vaccination. 
Na splošno se živa virusna in bakterijska cepiva ne smejo uporabljati pri bolnikih, ki prejemajo zdravilo za zaviranje imunske odzivnosti.
Metabolism and nutrition disorders Anorexia Hyperglycaemia 
Presnovne in prehranske motnje anoreksija hiperglikemija
Preparation of TEPADINA 
Priprava zdravila TEPADINA
Delirium Nervousness Hallucination Agitation 
Psihiatrične motnje stanje zmedenosti duševne motnje anksioznost delirij živčnost halucinacije vznemirjenost
Renal impairment The effects of renal impairment on thiotepa elimination have not been assessed. 
Vpliv na odstranjevanje tiotepe pri motnjah v delovanju ledvic ni bil ocenjen.
TEPADINA is used to prepare patients for bone marrow transplantation. 
Z zdravilom TEPADINA bolnike pripravljamo na presaditev kostnega mozga.
This leaflet was last revised in 
Navodilo je bilo nazadnje revidirano dne: Drugi viri informacij
- TEPADINA does not contain any other ingredients. 
- Zdravilo TEPADINA ne vsebuje pomožnih snovi.
TEPADINA is a white crystalline powder supplied in a glass vial containing 100 mg thiotepa. 
Zdravilo TEPADINA je bel kristalinični prašek, na voljo v stekleni viali, ki vsebuje 100 mg tiotepe.
Daily white blood cell counts and platelet counts are recommended during therapy with thiotepa and after transplant for at least 30 days. 
Med zdravljenjem s tiotepo in najmanj 30 dni po presaditvi je treba dnevno preverjati sliko belih krvnih celic in število trombocitov.
Thiotepa Read this guide prior to the preparation and administration of TEPADINA. 
Tiotepa Pred pripravo in uporabo zdravila TEPADINA preberite to navodilo.
LYMPHOMA The recommended dose ranges from 125 mg/m2/day (3.38 mg/kg/day) to 300 mg/m2/day 
Priporočeni odmerek pri hematoloških boleznih je od 125 mg mg/m2 na dan (3,38 mg/kg/dan) do
Musculoskeletal and connective tissue disorders 
Bolezni mišično-skeletnega sistema in vezivnega tkiva zastoj rasti
Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being 60% or lower, which was considered by the physicians as the threshold to prove efficacy. 
Ponovitev bolezni: pri vseh pripravljalnih zdravljenjih s tiotepo so poročali o stopnjah ponovitve po več kot enem letu v višini 60 % ali manj, kar zdravniki označujejo kot prag za dokazovanje učinkovitosti.
Liver failure 
Ledvična okvara
If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water (see section 
Če pride tiotepa nenamerno v stik s sluznico, sluznico temeljito sperite z vodo (glejte poglavje 6.6).
SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING 
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE IN RAVNANJE Z ZDRAVILOM
Headache Encephalopathy Convulsion Cerebral haemorrhage Memory impairment Paresis 
Bolezni živčevja glavobol encefalopatija konvulzije možganska krvavitev motnje spomina pareza ataksija
TEPADINA is a white crystalline powder supplied in a glass vial containing 15 mg thiotepa. 
Zdravilo TEPADINA je bel kristalinični prašek, na voljo v stekleni viali, ki vsebuje 15 mg tiotepe.
Linearity /non linearity There is no clear evidence of saturation of metabolic clearance mechanisms at high doses of thiotepa. 
Ni jasnih dokazov o zasičenosti mehanizmov presnovnega očistka pri visokih odmerkih tiotepe.
• with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; 
pred alogensko ali avtologno presaditvijo krvotvornih matičnih celic (PKMC) pri hematoloških boleznih pri odraslih in pediatričnih bolnikih;
Disease Free Survival (DFS): Percentages reported with follow-up periods of more than 1 year and up to 5 years confirm that conditioning treatments containing thiotepa following allogeneic HPCT are effective choices for treating patients with haematological diseases. 
Preživetje brez ponovitve bolezni: Odstotki, o katerih so poročali v nadaljnjem obdobju več kot enega leta in do pet let potrjujejo, da so pripravljalna zdravljenja s tiotepo po alogenski PKMC učinkovita izbira za zdravljenje bolnikov s hematološkimi boleznimi.
It is likely that certain adverse reactions of thiotepa like dizziness, headache and blurred vision could affect these functions. 
Zelo verjetno je, da lahko nekateri neželeni učinki tiotepe, kot so omotica, glavobol in zamegljen vid,
Disease Free Survival (DFS): An estimated 43% at five years has been reported, confirming that conditioning treatments containing thiotepa following autologous HPCT are effective therapeutic strategies for treating patients with haematological diseases. 
Preživetje brez ponovitve bolezni (DFS: Disease Free Survival): poročila navajajo ocenjenih 43 % pri petletnem preživetju brez ponovitve bolezni, kar potrjuje, da so pripravljalna zdravljenja s tiotepo po avtologni PKMC učinkovite terapevtske strategije za zdravljenje bolnikov s hematološkimi boleznimi.
Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being lower than 60%, which was considered by the physicians as the threshold to prove efficacy. 
Ponovitev bolezni: pri vseh pripravljalnih zdravljenjih s tiotepo so poročali o stopnjah ponovitve v obdobju več kot enega leta v manj kot 60 %, kar zdravniki označujejo kot prag za dokazovanje učinkovitosti.
Acute graft versus host disease Chronic graft versus host disease 
Bolezni imunskega sistema akutna reakcija presadka proti gostitelju kronična reakcija presadka proti gostitelju
CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to decreased concentrations of the active 4-OHCP. 
CYP2B6 katalizira presnovno pretvorbo ciklofosfamida v njegovo aktivno obliko 4-hidroksi ciklofosfamid (4
Disease Free Survival (DFS): Percentages reported with follow-up periods of more than 1 year confirm that conditioning treatments containing thiotepa following autologous HPCT are effective choices for treating patients with solid tumours. 
Preživetje brez ponovitve bolezni: odstotki, o katerih so poročali v nadaljnjem obdobju več kot enega leta, potrjujejo, da so pripravljalna zdravljenja s tiotepo po avtologni PKMC učinkovita izbira za zdravljenje bolnikov s čvrstimi tumorji.
TEPADINA must be reconstituted and diluted prior to administration. 
Zdravilo TEPADINA je treba pred uporabo rekonstituirati in razredčiti.
Venoocclusive liver disease Hepatomegaly Jaundice 
žolčnika in žolčevodov venookluzivna bolezen jeter hepatomegalija zlatenica
Chemical and physical in-use stability after reconstitution has been demonstrated for 8 hours when stored at 2°C-8°C. 
Dokazano je bilo, da je rekonstituirana raztopina kemijsko in fizikalno stabilna 8 ur, če je bila hranjena pri 2 °C-8 °C.
The reconstituted solution is hypotonic and must be further diluted prior to administration with 500 ml sodium chloride 9 mg/ml (0.9%) solution for injection (1000 ml if the dose is higher than 500 mg) or with an appropriate volume of sodium chloride 9 mg/ml (0.9%) in order to obtain a final TEPADINA concentration between 0.5 and 1 mg/ml. 
500 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje (če je predpisan odmerek večji od 500 mg, uporabite 1000 ml) ali z ustrezno količino natrijevega klorida 9 mg/ml (0,9 %), da dosežeto končno koncentracijo zdravila TEPADINA med 0.5 in 1 mg/ml.
One vial contains 15 mg thiotepa. 
Ena viala vsebuje 15 mg tiotepe.
Solutions containing a precipitate should be discarded. 
Raztopine, ki vsebujejo oborino, zavrzite.
Enteritis Intestinal obstruction 
- limfatična obstrukcija
One vial contains 100 mg thiotepa. 
Ena viala vsebuje 100 mg tiotepe.
- inflammation and exfoliation of the skin (erythrodermic psoriasis) - delirium, nervousness, hallucination, agitation - gastrointestinal ulcer - inflammation of the muscular tissue of the heart (myocarditis) - abnormal heart condition (cardiomyopathy) 
- vnetje in luščenje kože (eritrodermična psoriaza) - delirij, živčnost, halucinacije, vznemirjenost
The total volume of reconstituted vials to be administered should be further diluted in 500 ml of sodium chloride 9 mg/ml (0.9%) solution for injection prior to administration (1000 ml if the dose is higher than 500 mg). 
Skupno prostornino viale je treba pred injiciranjem nadalje razredčiti z dodajanjem 500 ml natrijevega klorida 9 mg/ml (0,9 %) (če je predpisan odmerek večji od 500 mg, uporabite 1000 ml).
Thiotepa has not been studied in patients with hepatic impairment. 
Uporabe tiotepe pri bolnikih z okvaro jeter niso proučevali.
After dilution the product is stable for 24 hours when stored at 2°C -8°C and for 4 hours when stored at 25°C. 
Po redčenju je zdravilo stabilno 24 ur, če je shranjeno pri temperaturi 2 °C-8 °C, in 4 ure, če je shranjeno pri 25 °C.